Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis. - Freedland, Stephen J.; De Giorgi, Ugo; Tutrone, Ronald F.; Karsh, Lawrence Ivan; Ramirez-Backhaus, Miguel; Uchio, Edward M.; Tang, Yiyun; Croitoru, Ruslan; Rosales, Matt; Kalac, Matko; Wang, Fong; Shore, Neal D. (Journal of Clinical Oncology)